Key points
- The first diabetes-reference generic was authorized April 28, 2026.
- The first Wegovy-reference generic was authorized June 29, 2026.
- Authorization does not guarantee immediate stock, substitution, coverage or price.
What Health Canada authorized
Health Canada announced a Dr. Reddy’s semaglutide injection referencing Ozempic on April 28, 2026, a second diabetes-reference product from Apotex on May 1, and Sevmia from Apotex referencing Wegovy for chronic weight management on June 29.[1][2]
| Date | Regulatory milestone | Reference context |
|---|---|---|
| April 28 | First generic semaglutide injection authorized | Ozempic / type 2 diabetes |
| May 1 | Second generic semaglutide injection authorized | Ozempic / type 2 diabetes |
| June 29 | First generic semaglutide for chronic weight management authorized | Wegovy |
What “generic” means here
Health Canada described the products as complex synthetic generics reviewed against Canadian safety, efficacy and quality requirements. Authorization remains product- and indication-specific; the word generic does not collapse every semaglutide formulation into one prescription.[1][2]
What authorization does not establish
It does not establish current pharmacy stock, price, plan payment, substitution for a particular prescription or individual suitability. Verify the DIN in the DPD, then use the pharmacy quote method and coverage workflow.[4]
What requires future review
Health Canada’s submissions-under-review list and DPD records can change. This page will update only after a public regulatory record supports the change, not from patent stories, retailer listings or speculation.[3][4]
Sources
- Canada becomes first G7 country to approve a generic version of semaglutideHealth Canada · Checked August 14, 2026
- Canada approves first generic semaglutide for weight lossHealth Canada · Checked August 14, 2026
- Generic submissions under reviewHealth Canada · Checked August 14, 2026
- Drug Product DatabaseHealth Canada · Checked August 14, 2026